Now showing items 1-2 of 2

    • Joll II, Jeffery Ethan; 0000-0001-7941-6380 (2022-03-15)
      Department: Biomedical Engineering
      In 2017 the sclerostin targeting monoclonal antibody Romosozumab was approved as a treatment for post-menopausal osteoporosis (PMO) despite cardiovascular side effects discovered in clinical trials. Previous studies indicated ...
    • Bowler, Meghan Allardyce (2018-04-11)
      Department: Biomedical Engineering
      Calcific aortic valve disease affects a quarter of those over 65 in the US alone. The only treatment is aortic valve replacement, but this intervention carries with it a high rate of morbidity and mortality and is often a ...